Liver Cancer Summit 2023
April 20-22, 2023 | Estoril, Portugal
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Conference & Exhibits
March 29 - April 01, 2023 | Montreal, QC, Canada
Multidisciplinary NET Medical Symposium 2023
October 05-07, 2023 | Montréal, QC, Canada
Multidisciplinary NET Medical Symposium 2024
October 12-14, 2024 | Chicago, IL, United States
Etrolizumab vs. infliximab for moderate to severely active ulcerative colitis treatment (GARDENIA)
The Lancet: Gastroenterology & Hepatology
Intensive versus standard drug therapy for symptomatic Crohn's disease strictures (STRIDENT)
The Lancet: Gastroenterology & Hepatology
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST)
The Lancet: Gastroenterology & Hepatology
AJM300 (carotegrast methyl), an oral alpha4-integrin antagonist, for patients with moderate ulcerative colitis: a phase 3 trial
The Lancet: Gastroenterology & Hepatology
Statin use and reduced hepatocellular carcinoma risk in patients with non- alcoholic fatty liver disease
Clinical Gastroenterology and Hepatology
Guselkumab for the treatment of Crohn disease: Induction results from the phase 2 GALAXI-1 study
Gastroenterology
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)
Diabetes, Obesity and Metabolism
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomized, open-label, phase 2 trial
The Lancet: Gastroenterology & Hepatology
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial
The Lancet: Gastroenterology & Hepatology
Rectal indomethacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): A single-center, double-blind, randomized, placebo-controlled trial
The Lancet: Gastroenterology & Hepatology